The Zacks Analyst Blog Highlights: United Therapeutics, TESARO, Supernus, BioSpecifics Technologies and Medicines Co.

Zacks

For Immediate Release
 
Chicago, IL – January 03, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United Therapeutics (UTHR-Free Report), TESARO, Inc. (TSRO-Free Report), Supernus (SUPN-Free Report), BioSpecifics Technologies Corp. (BSTC-Free Report) and Medicines Company (MDCO-Free Report).
 
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

Biotech Stock Roundup

With the holiday season in full swing, it’s been a slow week for the biotech sector. That being said, some companies that made headlines last week include United Therapeutics (UTHR-Free Report) and TESARO, Inc. (TSRO-Free Report).

Early Christmas for UTHR: The FDA played Santa for UTHR with the agency approving Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (:PAH) in WHO Group I patients to improve exercise capacity. It proved to be third time lucky for the company which had already received two complete response letters from the FDA earlier for the drug. Shares shot up 30.6% on the surprise approval and hit a 52-week high as well.

Supernus (SUPN-Free Report), UTHR’s partner, also benefited from the news with shares soaring 8%. Supernus stands to receive a milestone payment as well as royalties on Orenitram sales.

Investors Not Impressed with TESARO Data: Even though TESARO presented phase III data on its oncology candidate, rolapitant, saying that it achieved the primary endpoints in the studies, investors were not impressed - reason being the failure to achieve the secondary endpoints. Rolapitant is being developed for the prevention of chemotherapy-induced nausea and vomiting (:CINV). Shares plunged 24.7% on the data.

Other Developments:

BSTC’s CCH Fails in Phase II Study: BioSpecifics Technologies Corp.’s (BSTC-Free Report) collagenase clostridium histolyticum (CCH) failed to meet the primary endpoint in a phase II study that was being conducted in canines with benign subcutaneous lipomas. A human lipoma study is ongoing with results due this month. Shares were not impacted significantly by the news.

EMA Accepts Cangrelor Marketing Application: The European Medicines Agency (:EMA) has accepted The Medicines Company’s (MDCO-Free Report) regulatory application for its experimental intravenous antiplatelet agent, cangrelor. Cangrelor is currently under review in the U.S. as well.

RedHill Shares Gain on Positive Data: Shares of RedHill Biopharma inched up almost 4% on positive data from a pharmacokinetic (:PK) study on RHB-105. RHB-105 is being evaluated for the eradication of Helicobacter pylori (H. pylori) infection, which is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa associated lymphoid tissue (:MALT) lymphoma.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
 
Get the full Report on UTHR - FREE
Get the full Report on TSRO - FREE
Get the full Report on SUPN - FREE
Get the full Report on BSTC - FREE
Get the full Report on MDCO - FREE
 
Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on UTHR

Read the analyst report on TSRO

Read the analyst report on SUPN

Read the analyst report on BSTC

Read the analyst report on MDCO


Zacks Investment Research

Rates

View Comments (1)